Bristol Myers enters multi-year strategic collaboration with Repertoire

Repertoire announced that it has entered a multi-year strategic collaboration with Bristol Myers Squibb to develop tolerizing vaccines for up to three autoimmune diseases. The collaboration aims to develop efficacious, selective, and durable treatments for patients suffering from autoimmune disease by resetting the immune system. Under the terms of the agreement, Repertoire will receive an upfront payment of $65M, and up to $1.8B for achieving development, regulatory and commercial milestones in addition to receiving tiered royalties. Repertoire will lead all activities through to development candidate nomination, while BMS will lead clinical development, regulatory affairs, and commercialization of the tolerizing vaccines under an exclusive world-wide license. Repertoire will utilize its T cell receptor-epitope discovery platform, DECODE, and its proprietary lipid nanoparticle delivery technology to discover and develop the tolerizing vaccine development candidates. In addition, it will deploy DECODE to monitor immune responses to the tolerizing vaccines in patients during clinical development to provide key insights into the pharmacodynamic effect of the vaccines.